Advertisement

Treatment of Juvenile Idiopathic Arthritis in the Biologic Age

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Rheumatic Disease Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Petty R.E.
        • Southwood T.R.
        • Manners P.
        • et al.
        International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001.
        J Rheumatol. 2004; 31: 390-392
        • Ravelli A.
        • Felici E.
        • Magni-Manzoni S.
        • et al.
        Patients with antinuclear antibody-positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease.
        Arthritis Rheum. 2005; 52: 826-832
        • Tebo A.E.
        • Jaskowski T.
        • Davis K.W.
        • et al.
        Profiling anti-cyclic citrullinated peptide antibodies in patients with juvenile idiopathic arthritis.
        Pediatr Rheumatol Online J. 2012; 10: 29
        • Stoll M.L.
        • Zurakowski D.
        • Nigrovic L.E.
        • et al.
        Patients with juvenile psoriatic arthritis comprise two distinct populations.
        Arthritis Rheum. 2006; 54: 3564-3572
        • Stoll M.L.
        • Bhore R.
        • Dempsey-Robertson M.
        • et al.
        Spondyloarthritis in a pediatric population: risk factors for sacroiliitis.
        J Rheumatol. 2010; 37: 2402-2408
        • Ravelli A.
        • Grom A.A.
        • Behrens E.M.
        • et al.
        Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment.
        Genes Immun. 2012; 13: 289-298
        • Behrens E.M.
        • Beukelman T.
        • Gallo L.
        • et al.
        Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR).
        J Rheumatol. 2008; 35: 343-348
        • Giannini E.H.
        • Ruperto N.
        • Ravelli A.
        • et al.
        Preliminary definition of improvement in juvenile arthritis.
        Arthritis Rheum. 1997; 40: 1202-1209
        • Lehman T.J.
        Are withdrawal trials in paediatric rheumatic disease helpful?.
        Lancet. 2008; 372: 348-350
        • Beukelman T.
        • Patkar N.M.
        • Saag K.G.
        • et al.
        2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features.
        Arthritis Care Res (Hoboken). 2011; 63: 465-482
        • Haroon N.
        • Kim T.H.
        • Inman R.D.
        NSAIDs and radiographic progression in ankylosing spondylitis. Bagging big game with small arms?.
        Ann Rheum Dis. 2012; 71: 1593-1595
        • Gotte A.C.
        Intra-articular corticosteroids in the treatment of juvenile idiopathic arthritis: safety, efficacy, and features affecting outcome. A comprehensive review of the literature.
        Open Access Rheumatol Res Rev. 2009; 1: 37-49
        • Zulian F.
        • Martini G.
        • Gobber D.
        • et al.
        Triamcinolone acetonide and hexacetonide intra-articular treatment of symmetrical joints in juvenile idiopathic arthritis: a double-blind trial.
        Rheumatology (Oxford). 2004; 43: 1288-1291
        • Stoll M.L.
        • Sharpe T.
        • Beukelman T.
        • et al.
        Risk factors for temporomandibular joint arthritis in children with juvenile idiopathic arthritis.
        J Rheumatol. 2012; 39: 1880-1887
        • Beukelman T.
        • Ringold S.
        • Davis T.E.
        • et al.
        Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry.
        J Rheumatol. 2012; 39: 1867-1874
        • Kemper A.R.
        • Van Mater H.A.
        • Coeytaux R.R.
        • et al.
        Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis.
        BMC Pediatr. 2012; 12: 29
        • Prieur A.M.
        • Quartier P.
        Comparative tolerability of treatments for juvenile idiopathic arthritis.
        BioDrugs. 2000; 14: 159-183
        • Brooks C.D.
        Sulfasalazine for the management of juvenile rheumatoid arthritis.
        J Rheumatol. 2001; 28: 845-853
        • Silverman E.
        • Mouy R.
        • Spiegel L.
        • et al.
        Leflunomide or methotrexate for juvenile rheumatoid arthritis.
        N Engl J Med. 2005; 352: 1655-1666
        • Prakash A.
        • Jarvis B.
        Leflunomide: a review of its use in active rheumatoid arthritis.
        Drugs. 1999; 58: 1137-1164
        • Zuber Z.
        • Rutkowska-Sak L.
        • Postepski J.
        • et al.
        Etanercept treatment in juvenile idiopathic arthritis: the Polish registry.
        Med Sci Monit. 2011; 17: SR35-SR42
        • Sevcic K.
        • Orban I.
        • Brodszky V.
        • et al.
        Experiences with tumour necrosis factor-{alpha} inhibitors in patients with juvenile idiopathic arthritis: Hungarian data from the National Institute of Rheumatology and Physiotherapy Registry.
        Rheumatology (Oxford). 2011; 50: 1337-1340
        • Prince F.H.
        • Twilt M.
        • ten Cate R.
        • et al.
        Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register.
        Ann Rheum Dis. 2009; 68: 635-641
        • Giannini E.H.
        • Ilowite N.T.
        • Lovell D.J.
        • et al.
        Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis.
        Arthritis Rheum. 2009; 60: 2794-2804
        • Lovell D.J.
        • Giannini E.H.
        • Reiff A.
        • et al.
        Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group.
        N Engl J Med. 2000; 342: 763-769
        • Smith J.A.
        • Thompson D.J.
        • Whitcup S.M.
        • et al.
        A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis.
        Arthritis Rheum. 2005; 53: 18-23
        • Ruperto N.
        • Lovell D.J.
        • Cuttica R.
        • et al.
        A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis.
        Arthritis Rheum. 2007; 56: 3096-3106
        • Ruperto N.
        • Lovell D.J.
        • Quartier P.
        • et al.
        Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial.
        Lancet. 2008; 372: 383-391
        • Lovell D.J.
        • Ruperto N.
        • Goodman S.
        • et al.
        Adalimumab with or without methotrexate in juvenile rheumatoid arthritis.
        N Engl J Med. 2008; 359: 810-820
        • Yokota S.
        • Imagawa T.
        • Mori M.
        • et al.
        Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.
        Lancet. 2008; 371: 998-1006
        • Ilowite N.
        • Porras O.
        • Reiff A.
        • et al.
        Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study.
        Clin Rheumatol. 2009; 28: 129-137
        • Quartier P.
        • Allantaz F.
        • Cimaz R.
        • et al.
        A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial).
        Ann Rheum Dis. 2011; 70: 747-754
        • Tynjala P.
        • Vahasalo P.
        • Tarkiainen M.
        • et al.
        Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial.
        Ann Rheum Dis. 2011; 70: 1605-1612
        • Horneff G.
        • Fitter S.
        • Foeldvari I.
        • et al.
        Double blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement.
        Arthritis Res Ther. 2012; 14: R230
        • Wallace C.A.
        • Giannini E.H.
        • Spalding S.J.
        • et al.
        Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis.
        Arthritis Rheum. 2012; 64: 2012-2021
        • De Benedetti F.
        • Brunner H.I.
        • Ruperto N.
        • et al.
        Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis.
        N Engl J Med. 2012; 367: 2385-2395
        • Ruperto N.
        • Brunner H.I.
        • Quartier P.
        • et al.
        Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.
        N Engl J Med. 2012; 367: 2396-2406
        • Horneff G.
        • Schmeling H.
        • Biedermann T.
        • et al.
        The German etanercept registry for treatment of juvenile idiopathic arthritis.
        Ann Rheum Dis. 2004; 63: 1638-1644
        • Brunner H.
        • Ruperto N.
        • Zuber Z.
        • et al.
        Efficacy of safety of tocilizumab in patients with polyarticular juvenile idiopathic arthritis: data from a phase 3 trial.
        Arthritis Rheum. 2012; 64 ([abstract]): S682
        • Fox D.A.
        Biological therapies: a novel approach to the treatment of autoimmune disease.
        Am J Med. 1995; 99: 82-88
        • Stoll M.L.
        • Gotte A.C.
        Biological therapies for the treatment of juvenile idiopathic arthritis: lessons from the adult and pediatric experiences.
        Biologics. 2008; 2: 229-252
        • Southwood T.R.
        • Foster H.E.
        • Davidson J.E.
        • et al.
        Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients.
        Rheumatology (Oxford). 2011; 50: 189-195
        • Quartier P.
        • Taupin P.
        • Bourdeaut F.
        • et al.
        Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type.
        Arthritis Rheum. 2003; 48: 1093-1101
        • Foeldvari I.
        • Nielsen S.
        • Kummerle-Deschner J.
        • et al.
        Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey.
        J Rheumatol. 2007; 34: 1146-1150
        • Assasi N.
        • Blackhouse G.
        • Xie F.
        • et al.
        Patient outcomes after anti TNF-alpha drugs for Crohn's disease.
        Expert Rev Pharmacoecon Outcomes Res. 2010; 10: 163-175
        • Horneff G.
        • De Bock F.
        • Foeldvari I.
        • et al.
        Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry.
        Ann Rheum Dis. 2009; 68: 519-525
        • Trachana M.
        • Pratsidou-Gertsi P.
        • Pardalos G.
        • et al.
        Safety and efficacy of adalimumab treatment in Greek children with juvenile idiopathic arthritis.
        Scand J Rheumatol. 2011; 40: 101-107
        • Sukumaran S.
        • Marzan K.
        • Shaham B.
        • et al.
        High dose infliximab in the treatment of refractory uveitis: does dose matter?.
        ISRN Rheumatol. 2012; 2012: 765380
      1. Tambralli A, Beukelman T, Weiser P, et al. High doses of infliximab in the management of juvenile idiopathic arthritis. J Rheumatol, in press.

        • Tse S.M.
        • Burgos-Vargas R.
        • Laxer R.M.
        Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy.
        Arthritis Rheum. 2005; 52: 2103-2108
        • Stoll M.L.
        • Punaro M.
        Psoriatic juvenile idiopathic arthritis: a tale of two subgroups.
        Curr Opin Rheumatol. 2011; 23: 437-443
        • Diak P.
        • Siegel J.
        • La Grenade L.
        • et al.
        Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration.
        Arthritis Rheum. 2010; 62: 2517-2524
        • Cron R.Q.
        • Beukelman T.
        Guilt by association—what is the true risk of malignancy in children treated with etanercept for JIA?.
        Pediatr Rheumatol Online J. 2010; 8: 23
        • Beukelman T.
        • Haynes K.
        • Curtis J.R.
        • et al.
        Rates of malignancy associated with juvenile idiopathic arthritis and its treatment.
        Arthritis Rheum. 2012; 64: 1263-1271
        • Beukelman T.
        • Xie F.
        • Chen L.
        • et al.
        Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment.
        Arthritis Rheum. 2012; 64: 2773-2780
        • Dinarello C.A.
        • Simon A.
        • van der Meer J.W.
        Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases.
        Nat Rev Drug Discov. 2012; 11: 633-652
        • Nigrovic P.A.
        • Mannion M.
        • Prince F.H.
        • et al.
        Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series.
        Arthritis Rheum. 2011; 63: 545-555
        • Record J.L.
        • Beukelman T.
        • Cron R.Q.
        Combination therapy of abatacept and anakinra in children with refractory systemic juvenile idiopathic arthritis: a retrospective case series.
        J Rheumatol. 2011; 38: 180-181
        • Miettunen P.M.
        • Narendran A.
        • Jayanthan A.
        • et al.
        Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients.
        Rheumatology (Oxford). 2011; 50: 417-419
        • Mertens M.
        • Singh J.A.
        Anakinra for rheumatoid arthritis.
        Cochrane Database Syst Rev. 2009; (CD005121)
        • Cron R.Q.
        A signal achievement in the treatment of arthritis.
        Arthritis Rheum. 2005; 52: 2229-2232
        • Kenawy N.
        • Cleary G.
        • Mewar D.
        • et al.
        Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis.
        Graefes Arch Clin Exp Ophthalmol. 2011; 249: 297-300
        • Simon T.A.
        • Askling J.
        • Lacaille D.
        • et al.
        Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment.
        Arthritis Res Ther. 2010; 12: R67
        • Singh J.A.
        • Wells G.A.
        • Christensen R.
        • et al.
        Adverse effects of biologics: a network meta-analysis and Cochrane overview.
        Cochrane Database Syst Rev. 2011; (CD008794)
        • Ohsugi Y.
        Recent advances in immunopathophysiology of interleukin-6: an innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases.
        Biol Pharm Bull. 2007; 30: 2001-2006
        • Inaba Y.
        • Ozawa R.
        • Imagawa T.
        • et al.
        Radiographic improvement of damaged large joints in children with systemic juvenile idiopathic arthritis following tocilizumab treatment.
        Ann Rheum Dis. 2011; 70: 1693-1695
        • Ruderman E.M.
        Overview of safety of non-biologic and biologic DMARDs.
        Rheumatology (Oxford). 2012; 51: vi37-vi43
        • Woo P.
        • Wilkinson N.
        • Prieur A.M.
        • et al.
        Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement.
        Arthritis Res Ther. 2005; 7: R1281-R1288
        • Grillo-Lopez A.J.
        • White C.A.
        • Varns C.
        • et al.
        Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.
        Semin Oncol. 1999; 26: 66-73
        • Alexeeva E.I.
        • Valieva S.I.
        • Bzarova T.M.
        • et al.
        Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis.
        Clin Rheumatol. 2011; 30: 1163-1172
        • Heiligenhaus A.
        • Miserocchi E.
        • Heinz C.
        • et al.
        Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab).
        Rheumatology (Oxford). 2011; 50: 1390-1394
        • Kimby E.
        Tolerability and safety of rituximab (MabThera).
        Cancer Treat Rev. 2005; 31: 456-473
        • Molloy E.S.
        • Calabrese L.H.
        Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies.
        Arthritis Rheum. 2012; 64: 3043-3051
        • Hadjinicolaou A.V.
        • Nisar M.K.
        • Parfrey H.
        • et al.
        Non-infectious pulmonary toxicity of rituximab: a systematic review.
        Rheumatology (Oxford). 2012; 51: 653-662
        • Schneider R.
        • Laxer R.M.
        Systemic onset juvenile rheumatoid arthritis.
        Baillieres Clin Rheumatol. 1998; 12: 245-271